loviride loviride loviride is an experimental antiviral drug manufactured by janssen (now part of janssen-cilag) that is active against hiv. loviride is a non-nucleoside reverse transcriptase inhibitor (nnrti) that entered phase iii clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency. it is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., caesar and avanti), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as k103n which result in cross-class resistance to the nnrtis efavirenz and nevirapine. lovirideclinical dataother namesr089439; loverideatc codenoneidentifiers iupac name 2--2-(2,6-dichlorophenyl)acetamide cas number147362-57-0 npubchem cid3963chemspider3826 yunii3s1r1lz09hkeggd04786 ychemblchembl37624 ychemical and physical dataformulac17h16cl2n2o2molar mass351.23 g·mol−13d model (jsmol)interactive image smiles clc1cccc(cl)c1c(nc2cc(ccc2c(=o)c)c)c(=o)n inchi inchi=1s/c17h16cl2n2o2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21h,1-2h3,(h2,20,23) ykey:cjpleffcvdqqfz-uhfffaoysa-n y ny (what is this?) (verify)